DNTH
Dianthus Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$108.10
+0.23%0
Insider buys (3m)
30
Insider sells (3m)
-$29.7M
Net value (3m)
+33.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Randhawa Simrat · officer: EVP, Head of R&D | Sale | 7,215 | $106 |
| Sep 3, 2026 | Randhawa Simrat · officer: EVP, Head of R&D | Sale | 13,309 | $107 |
| Sep 3, 2026 | Randhawa Simrat · officer: EVP, Head of R&D | M-Exempt | 7,500 | $18 |
| Sep 3, 2026 | Randhawa Simrat · officer: EVP, Head of R&D | M-Exempt | 6,249 | $22 |
| Sep 3, 2026 | Randhawa Simrat · officer: EVP, Head of R&D | M-Exempt | 9,375 | $22 |
| Sep 3, 2026 | Randhawa Simrat · officer: EVP, Head of R&D | Sale | 2,600 | $105 |
| Aug 19, 2026 | Read Simon · director | M-Exempt | 2,778 | $18 |
| Aug 19, 2026 | Read Simon · director | Sale | 2,778 | $118 |
| Aug 14, 2026 | Veness Adam M · officer: SVP, General Counsel and Sec. | M-Exempt | 15,000 | $18 |
| Aug 11, 2026 | Read Simon · director | Sale | 831 | $109 |
| Aug 11, 2026 | Read Simon · director | Sale | 737 | $108 |
| Aug 11, 2026 | Read Simon · director | Sale | 70 | $107 |
| Aug 11, 2026 | Read Simon · director | M-Exempt | 2,777 | $18 |
| Aug 11, 2026 | McGeorge Anne · director | Sale | 700 | $111 |
| Aug 11, 2026 | McGeorge Anne · director | Sale | 1,000 | $111 |
| Aug 11, 2026 | McGeorge Anne · director | Sale | 1,800 | $109 |
| Aug 11, 2026 | McGeorge Anne · director | Sale | 2,800 | $108 |
| Aug 11, 2026 | McGeorge Anne · director | Sale | 1,450 | $108 |
| Aug 11, 2026 | McGeorge Anne · director | M-Exempt | 1,250 | $19 |
| Aug 11, 2026 | McGeorge Anne · director | M-Exempt | 6,500 | $11 |
| Aug 11, 2026 | Read Simon · director | Sale | 272 | $110 |
| Aug 11, 2026 | Read Simon · director | Sale | 470 | $111 |
| Aug 11, 2026 | Read Simon · director | Sale | 397 | $112 |
| Aug 11, 2026 | Veness Adam M · officer: SVP, General Counsel and Sec. | M-Exempt | 3,833 | $18 |
| Aug 11, 2026 | Veness Adam M · officer: SVP, General Counsel and Sec. | Sale | 3,217 | $111 |
| Aug 11, 2026 | Veness Adam M · officer: SVP, General Counsel and Sec. | Sale | 616 | $111 |
| Aug 11, 2026 | Veness Adam M · officer: SVP, General Counsel and Sec. | M-Exempt | 16,167 | $18 |
| Aug 11, 2026 | Veness Adam M · officer: SVP, General Counsel and Sec. | Sale | 16,167 | $110 |
| Aug 7, 2026 | Garcia Marino · director, officer: CEO AND PRESIDENT | M-Exempt | 126,000 | $8.44 |
| Aug 7, 2026 | Garcia Marino · director, officer: CEO AND PRESIDENT | Sale | 21,909 | $109 |
Institutional positioning
13F filings over the trailing two quarters
New 161Increased 201Reduced 124Sold out 32
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 8,199,893 | Aug 13, 2026 |
| FMR LLC | Increased | 7,767,686 | May 15, 2026 |
| BlackRock, Inc. | Increased | 4,123,822 | Aug 7, 2026 |
| T. Rowe Price Investment Management, Inc. | Increased | 3,888,456 | Aug 14, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 3,229,882 | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 3,175,703 | May 13, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Increased | 2,611,733 | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 2,595,783 | May 15, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Increased | 2,537,191 | May 15, 2026 |
| Fairmount Funds Management LLC | Unchanged | 2,537,191 | Aug 14, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 2,514,946 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 2,357,440 | Aug 7, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,159,568 | Aug 13, 2026 |
| AVIDITY PARTNERS MANAGEMENT LP | Unchanged | 2,104,184 | May 28, 2026 |
| Avidity Partners Management LP | Unchanged | 2,104,184 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 3, 2026